Please ensure Javascript is enabled for purposes of website accessibility

Ocugen Stock Crashes: What Should Investors Do Now?

By Keith Speights - Jun 15, 2021 at 5:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here are three steps to take.

Just a few days ago, Ocugen (OCGN 1.41%) was flying high with shares up more than 460% year to date. Investors were hopeful that the small drugmaker would be able to win U.S. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech.

On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. The company stated that it will pursue a path to file for full FDA approval of Covaxin. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing.

The biotech stock promptly crashed by more than 30%. What should investors do now? Here are three prudent steps to take.

A person with head down behind a laptop screen.

Image source: Getty Images.

1. Reevaluate the company's prospects 

Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. That's not going to happen now.

How long might it take for Ocugen to win full FDA approval for Covaxin? It's hard to say for sure.

It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available.

Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. For priority reviews, the timeline for an approval decision is reduced to six months.

Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now.

2. Look at all your alternatives

If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). This requires no immediate effort on your part.

Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. Investing is always a game of balancing risk and reward. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does.

Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. These options will be cheaper than owning the stock itself. If Ocugen goes up, you can still profit. If it goes down, your loss won't be as great as it would be if you held onto all of your shares.

3. Identify lessons learned

Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Those lessons will vary between different investors, but I'll point out a major one to keep in mind.

Companies will inevitably be optimistic about their prospects for success (at least publicly). However, sometimes the optimism isn't justified.

For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." Objective investors could have clearly seen then that there actually were significant reasons to be concerned.

It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. This can prove to be a costly lesson to learn.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.88 (1.41%) $0.04
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$176.78 (3.27%) $5.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.